Fennec Pharmaceuticals Inc.(FRX)

Description: Fennec Pharmaceuticals Inc., formerly Adherex Technologies Inc., is a biopharmaceutical company focused on cancer therapeutics. The Company's lead product candidate in the clinical stage of development includes Sodium Thiosulfate (STS), which has completed patient enrollment of over two Phase III clinical trials for the prevention of cisplatin induced hearing loss, or ototoxicity in children. STS has been studied by cooperative groups in over two Phase III clinical studies of survival and reduction of ototoxicity, The Clinical Oncology Group Protocol ACCL0431 and SIOPEL 6. The Children's Oncology Group (COG) ACCL0431 protocol enrolled 20% childhood cancers typically treated with intensive cisplatin therapy for localized and disseminated disease, including hepatoblastoma, germ cell tumor, osteosarcoma, neuroblastoma and medulloblastoma. SIOPEL 6 enrolled only hepatoblastoma patients with localized tumors.

---

Keywords: Pharmaceutical Cancer Biopharmaceutical Disease Clinic Oncology Tumor Clinical Trial Pharma Blastoma Brain Tumor Childhood Cancer Therapeutics Neuroblastoma Neoplasms Hearing Loss Osteosarcoma Localized Tumors Ototoxicity Pediatric Cancers % Childhood Cancers Accl0431 Accl0431 Protocol Cooperative Groups Germ Cell Tumor Hepatoblastoma Medulloblastoma Therapy For Localized And Disseminated Disease

---

Home Page: www.fennecpharma.com

FRX Technical Analysis

68 TW Alexander Drive
Research Triangle Park, NC 27709
United States
Phone: 919 636 4530

---

Officers

Exchange: TO

Country: CA

Currency: Canadian Dollar (C$)